An animal study to compare the degree of the suppressive effects on the afferent pathways of micturition between tamsulosin and sildenafil

Journal of Biomedical Science

Khae-Hawn Kim¹  Chang-Ju Kim²  Mal-Soon Shin²  In-Young Choi²  Lakkyong Hwang²  Il-Gyu Ko²  Sung-Eun Kim² 

[1] Department of Urology, Gil Medical Center, Gachon University, #1198 Guwol-dong, Namdong-gu, Incheon 405-760, Republic of Korea;Department of Physiology, College of Medicine, Kyung Hee University, #1 Hoigi-dong, Dongdaemoon-gu, Seoul 130-701, Republic of Korea

关键词: Afferent pathways of micturition;    Neuronal activity;    Sildenafil;    Tamsulosin;    Overactive bladder syndrome;   

Others  :  821919
DOI  :  10.1186/1423-0127-20-81

 received in 2013-06-25, accepted in 2013-10-21,  发布年份 2013

【 摘 要 】

Background

Tamsulosin, an α1-adrenoceptor antagonist, and sildenafil, a phosphodiesterase (PDE) inhibitor, are reported to improve lower urinary tract symptoms including overactive bladder (OAB). This study is aimed at investing the effects of tamsulosin and sildenafil and comparing the degree of the suppressive effects on the afferent pathways of micturition between them using an animal model of OAB, the spontaneously hypertensive rat (SHR).

Results

The cystometric parameters, the basal pressure and duration of bladder contraction, were significantly increased in the SHR group as compared with the Wistar-Kyoto (WKY) group. The intercontraction interval also significantly decreased in the SHR group. In the SHR-Tam 0.01 mg/kg group and the SHR-Sil 1 mg/kg group, however, the basal pressure and duration were significantly reduced and the intercontraction interval was significantly prolonged. Moreover, the degree of the expression of c-Fos and NGF was significantly higher in the SHR group as compared with the WKY group. But it was significantly reduced in the SHR-Tam 0.01 mg/kg group and the SHR-Sil 1 mg/kg group. Furthermore, tamsulosin had a higher degree of effect as compared with sildenafil.

Conclusions

In conclusion, α1-adrenergic receptor antagonists and PDE-5 inhibitors may have an effect in improving the voiding functions through an inhibition of the neuronal activity in the afferent pathways of micturition.

【 授权许可】

   
2013 Kim et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Parsons BA, Drake MJ: Animal models in overactive bladder research. Handb Exp Pharmacol 2011, 202:15-43.
• [2]Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L: Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006, 97:96-100.
• [3]Marson L: Identification of central nervous system neurons that innervate the bladder body, bladder base, or external urethral sphincter of female rats: a transneuronal tracing study using pseudorabies virus. J Comp Neurol 1997, 389:584-602.
• [4]Kavia RB, Dasgupta R, Fowler CJ: Functional imaging and the central control of the bladder. J Comp Neurol 2005, 493:27-32.
• [5]Blok BF: Brain control of the lower urinary tract. Scand J Urol Nephrol Suppl 2002, 210:11-15.
• [6]Kim SE, Shin MS, Kim CJ, Park JH, Chung KJ, Jung H, Kim KH, Lee JH, Ko IG: Effects of tamsulosin on urinary bladder function and neuronal activity in the voiding centers of rats with cyclophosphamide-induced overactive bladder. Int Neurourol J 2012, 16:13-22.
• [7]Dragunow M, Faull R: The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 1989, 29:261-265.
• [8]Cruz F: Mechanisms involved in new therapies for overactive bladder. Urology 2004, 63:65-73.
• [9]Giuliano F: Lower urinary tract symptoms and sexual dysfunction: a common approach. BJU Int 2008, 101(Suppl 3):22-26.
• [10]Montorsi F, Roehrborn C, Garcia-Penit J, Borre M, Roeleveld TA, Alimi JC, Gagnier P, Wilson TH: The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int 2011, 107:1426-1431.
• [11]Giuliano F: Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms. Eur Urol 2008, 53:1121-1123.
• [12]Ückert S, Oelke M: Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol 2011, 72:197-204.
• [13]McVary KT, Siegel RL, Carlsson M: Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008, 72:575-579.
• [14]McMurray G, Casey JH, Naylor AM: Animal models in urological disease and sexual dysfunction. Br J Pharmacol 2006, 147(Suppl 2):S62-S79.
• [15]Persson K, Pandita RK, Spitsbergen JM, Steers WD, Tuttle JB, Andersson KE: Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998, 275:R1366-R1373.
• [16]de Groat WC, Yoshimura N: Changes in afferent activity after spinal cord injury. Neurourol Urodyn 2010, 29:63-76.
• [17]Callsen-Cencic P, Mense S: Increased spinal expression of c-Fos following stimulation of the lower urinary tract in chronic spinal cord-injured rats. Histochem Cell Biol 1999, 112:63-72.
• [18]Holstege G: Micturition and the soul. J Comp Neurol 2005, 493:15-20.
• [19]Yotsuyanagi S, Yokoyama O, Komatsu K, Kodama K, Niikura S, Namiki M: Expression of neural plasticity related gene in the pontine tegmental area of rats with overactive bladder after cerebral infarction. J Urol 2001, 166:1148-1155.
• [20]Sugaya K, Nishijima S, Miyazato M, Ogawa Y: Central nervous control of micturition and urine storage. J Smooth Muscle Res 2005, 41:117-132.
• [21]Ochodnicky P, Cruz CD, Yoshimura N, Michel MC: Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 2011, 30:1227-1241.
• [22]Kuo HC, Liu HT, Chancellor MB: Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 2011, 29:482-487.
• [23]Yoshimura N, Bennett NE, Hayashi Y, Ogawa T, Nishizawa O, Chancellor MB, de Groat WC, Seki S: Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci 2006, 26:10847-10855.
• [24]Ko IG, Kim SE, Kim BK, Shin MS, Kim CJ, Yim SJ, Bang YJ, Choi IH, Kim KH: Swimming: effects on stress urinary incontinence and the expression of nerve growth factor in rats following transabdominal urethrolysis. Int Neurourol J 2011, 15:74-81.
• [25]Andersson KE: Overactive bladder-pharmacological aspects. Scand J Urol Nephrol Suppl 2002, 210:72-81.
• [26]Jeong MS, Lee JG: The role of spinal and peripheral α1- and α2-adrenoceptors on bladder activity induced by bladder distension in anaesthetized rat. BJU Int 2000, 85:925-931.
• [27]Haga N, Aikawa K, Ishibashi K, Yanagida T, Nomiya M, Takahashi N, Shiomi H, Oguro T, Ogawa S, Yamaguchi O: Long-term administration of prazosin improves bladder storage function: results from a study in spontaneously hypertensive rats. Int J Urol 2011, 18:785-791.
• [28]Yokoyama O: Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats. Neurourol Urodyn 2010, 29:107-111.
• [29]Andersson KE: Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol 2009, 1:71-83.
• [30]Caremel R, Oger-Roussel S, Behr-Roussel D, Grise P, Giuliano FA: Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol 2010, 58:616-625.